News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
10+ emerging markets, Japan & ANZ transition in final phase
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Robots make it to the healthcare conference panel, reflecting the future potential of technology
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
